FindTrial
Sign In

Efficacy of White Kidney Bean Extract to Prevent Kidney Injury in Obese Population: A Randomized Controlled Trial

Efficacy of White Kidney Bean Extract to Prevent Kidney Injury in Obese Population: A Randomized Controlled Trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
TCTR
Registry ID
TCTR20140323001
Enrollment
Unknown
Registered
2014-03-23
Start date
2013-10-14
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Early stage of obesity&#45

Interventions

Subjects given one 445 mg of Phase 2&#174
capsule plus one placebo capsule per meal orally thrice daily 30 minutes before each meal. ,Subjects given two 500 mg of Phase 2&#174
capsules per meal orally thrice daily 30 minutes before each meal.,Subjects given two placebo capsules per meal orally thrice daily 30 minutes before each meal.
Experimental Dietary Supplement,Experimental Dietary Supplement,Placebo Comparator No treatment
Low dose white kidney bean extract group,High dose white kidney bean extract group,Placebo group

Sponsors

Pharmachem Laboratories, Inc.
Lead Sponsor
Clinical Research Center&#44
Collaborator
Department of Medicine&#44
Collaborator
Phramongkutklao hospital and College of Medicine
Collaborator

Eligibility

Sex/Gender
All
Age
20 Years to 50 Years

Inclusion criteria

Inclusion criteria: Non diabetic Thai healthy obese subjects Body mass index 25 to 33 kg m2 Normal baseline serum creatinine Normal complete blood count and liver function test

Exclusion criteria

Exclusion criteria: Uncontrolled obesity related co morbidities Using of weight reduction agents within 4 weeks prior to study History of bariatric surgery Pregnancy and breast feeding female Other active glomerular diseases Active malignancy History of bean allergy or G6PD deficiency Drug abuse or alcohol drinking or smoking

Design outcomes

Primary

MeasureTime frame
Urinary Cystatin C-creatinine ratio (UCCR) After randomization (day 0) and at 12 weeks (complete the study) 10 mL first morning urine is measured for UCCR—

Secondary

MeasureTime frame
Urinary albumin-creatinine ratio (UACR) After randomization (day 0) and at 12 weeks (complete the study) 10 mL first morning urine is measured for UACR,High sensitivity C-reactive protein (hs-CRP) After randomization (day 0) and at 12 weeks (complete the study) Blood measurement,Fasting plasma glucose After randomization (day 0) and at 12 weeks (complete the study) Blood measurement,Lipid profiles (total cholesterol, low density lipoprotein, high density lipoprotein, triglyceride) After randomization (day 0) and at 12 weeks (complete the study) Blood measurement—

Contacts

Public ContactVeerapatr Nimkietkajorn

Division of Nephrology, Department of Medicine, Phramongkutklao Hospital and College of Medicine

pukasm@gmail.com(66) 02-354-7600

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026